AYTU BIOPHARMA, INC
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 7900 E. UNION AVENUE, DENVER, CO, 80237
Mailing Address 7900 E. UNION AVENUE, DENVER, CO, 80237
Phone (720) 437-6580
Fiscal Year End 0630
EIN 470883144
Financial Overview
FY2025
-$13.56M
Net Income
$124.18M
Total Assets
$27.72M
Stockholders' Equity
$30.95M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 8-K Current report of material events | February 3, 2026 | View on SEC |
| 10-Q Quarterly financial report | February 3, 2026 | View on SEC |
| 8-K Current report of material events | January 20, 2026 | View on SEC |
| 8-K Current report of material events | December 10, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| 8-K Current report of material events | November 13, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 12, 2025 | View on SEC |
| DEF 14A Definitive proxy statement | October 24, 2025 | View on SEC |
Annual Reports
10-K September 23, 2025
- Maintained ADHD drug supplies during industry-wide shortages
- Preparing to launch EXXUA, a new antidepressant, in 2025
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.